Training and Resources
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
KEYTRUDA® (pembrolizumab) in adjuvant renal cell carcinoma (RCC)
RCC Pre-Operative Considerations & Post-Operative MDT Decision Aid
GB-RCC-00497 | Date of Preparation: November 2022
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
KEYNOTE-564 interactive slide deck
GB-RCC-00698 | Date of Preparation: October 2023
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
Adjuvant RCC patient identification guide
GB-RCC-00489 | Date of Preparation: October 2022
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
For more information about KEYTRUDA in adjuvant RCC:
KEYTRUDA in advanced renal cell carcinoma (aRCC)
Patient assets
To order printed versions of these diaries to your place of work, please contact msdukoncology@msd.com.
KEYTRUDA® (pembrolizumab) in combination with KISPLYX® (lenvatinib) patient booklet and diary
GB-KLR-00097 | Date of Preparation: October 2022
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
Please be aware you should not direct your patient to this website. You should download this diary on their behalf and share it with them as appropriate.
HCP treatment optimisation guide
Your guide to recognising and managing KEYTRUDA® (pembrolizumab) plus KISPLYX® (lenvatinib) adverse events in aRCC
For full information about KEYTRUDA and KISPLYX adverse events, please refer to each product’s individual SmPC
GB-KLR-00098 | Date of Preparation: February 2023
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
For more information about KEYTRUDA in advanced RCC:
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
